Argos Therapeutics (ARGS) 10-Q 15 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 08, 2016
Document Information [Line Items]
Entity Registrant Name	ARGOS THERAPEUTICS INC
Entity Central Index Key	1,105,533
Trading Symbol	args
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		41,196,695
Document Type	10-Q
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 34,830,164	$ 6,163,144
Short-term investments		1,003,160
Restricted cash	740,000	740,000
Prepaid expenses	1,247,696	740,173
Other receivables	461,143	73,818
Total current assets	37,279,003	8,720,295
Property and equipment, net	29,145,088	22,306,384
Other assets	11,020	11,020
Total assets	66,435,111	31,037,699
Current liabilities
Accounts payable	5,135,238	2,907,683
Accrued expenses	3,831,736	3,676,846
Research and Development Obligation, Current	2,122,661
Current portion of notes payable	6,787,283	1,578,284
Total current liabilities	17,876,918	8,162,813
Long-term portion of notes payable	24,503,569	30,728,258
Long-term portion of manufacturing research and development obligation	5,854,880	7,777,436
Long-term portion of facility lease obligation	7,159,627	7,249,627
Deferred Credits and Other Liabilities, Noncurrent	6,778,500	5,321,000
Stockholders’ (deficit) equity
Preferred stock $0.001 par value; 5,000,000 shares authorized as of December 31, 2015 and June 30, 2016; 0 shares issued and outstanding as of December 31, 2015 and June 30, 2016	0	0
Common stock $0.001 par value; 200,000,000 shares authorized as of December 31, 2015 and June 30, 2016; 21,641,509 and 32,031,452 shares issued and outstanding as of December 31, 2015 and June 30, 2016, respectively	32,031	21,642
Accumulated other comprehensive loss	(129,837)	(138,245)
Additional paid-in capital	308,744,563	250,873,875
Accumulated deficit	(304,385,140)	(278,958,707)
Total stockholders’ (deficit) equity	4,261,617	(28,201,435)
Total liabilities and stockholders’ (deficit) equity	$ 66,435,111	$ 31,037,699

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	32,031,452	21,641,509
Common stock, shares outstanding (in shares)	32,031,452	21,641,509

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue	$ 488,643	$ 107,391	$ 635,072	$ 286,162
Operating expenses
Research and development	9,164,184	16,084,834	18,666,160	30,851,816
General and administrative	3,389,479	2,909,358	6,364,503	5,280,559
Total operating expenses	12,553,663	18,994,192	25,030,663	36,132,375
Operating loss	(12,065,020)	(18,886,801)	(24,395,591)	(35,846,213)
Other expense
Interest income	2,237	8,327	3,813	18,415
Interest expense	(543,462)	(725,522)	(1,034,655)	(1,320,437)
Other expense		(822)		(2,798)
Other expense, net	(541,225)	(718,017)	(1,030,842)	(1,304,820)
Net loss	$ (12,606,245)	$ (19,604,818)	$ (25,426,433)	$ (37,151,033)
Net loss per share, basic and diluted (in dollars per share)	$ (0.48)	$ (0.95)	$ (1.04)	$ (1.84)
Weighted average shares outstanding, basic and diluted (in shares)	26,066,160	20,622,326	24,336,393	20,145,747

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Net loss	$ (12,606,245)	$ (19,604,818)	$ (25,426,433)	$ (37,151,033)
Other comprehensive gain (loss)
Foreign currency translation gain (loss)	181	3,368	8,137	(9,493)
Unrealized gain on short-term investments		2,368	271	7,363
Total comprehensive loss	$ (12,606,064)	$ (19,599,082)	$ (25,418,025)	$ (37,153,163)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities
Net loss	$ (25,426,433)	$ (37,151,033)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	439,738	347,962
Compensation expense related to stock options	2,497,254	1,766,853
Common stock issued as payment for services	149,815
Interest accrued/(capitalized) on long-term debt	(404,113)	457,891
Amortization of debt discount	70,408	49,834
Amortization of debt issuance costs	17,002	138,615
Loss on disposal of equipment		2,799
Changes in operating assets and liabilities:
Prepaid expenses and other receivables	(894,849)	68,609
Other assets		(441,570)
Accounts payable	378,776	2,058,051
Accrued expenses	1,134,276	1,000,050
Deferred liabilities	(82,500)	1,512,500
Manufacturing research and development obligation	200,104	781,350
Net cash used in operating activities	(21,920,522)	(29,408,089)
Cash flows from investing activities
Purchase of property and equipment	(5,635,239)	(5,010,684)
Purchase of short-term investments		(2,743,176)
Proceeds from maturity of short-term investments	1,003,431	14,202,000
Net cash provided by (used in) investing activities	(4,631,808)	6,448,140
Cash flows from financing activities
Proceeds from sale of common stock and warrants	54,826,380	8,570,000
Proceeds from exercise of common stock warrants	299,932
Stock issuance costs	(75,188)
Payments on notes payable	(9,538)	(25,740)
Payment on facility lease obligation	(100,000)
Proceeds from exercise of common stock options	132,772	93,396
Proceeds from exercise of employee stock purchase plan	136,958	100,082
Net cash provided by financing activities	55,211,316	8,737,738
Effect of exchange rate changes on cash	8,034	(9,412)
Net (decrease) increase in cash and cash equivalents	28,667,020	(14,231,623)
Beginning of period	6,163,144	37,223,590
End of period	34,830,164	22,991,967
Supplemental disclosure of cash flow information
Cash paid for interest	974,526	583,808
Supplemental disclosure of noncash investing and financing activities
Stock issuance costs included in accounts payable and accrued expenses	803,352
Interest capitalized on construction-in-progress	850,551
Purchase of property and equipment included in accounts payable and accrued expenses	782,548	1,135,437
Recognition of asset and facility lease obligation related to construction of new property	$ 10,000	$ 4,240,437

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Organization and Basis of Presentation Argos Therapeutics, Inc. (the “Company”), was incorporated in the State of Delaware on May 8, 1997. The Company is an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer using its Arcelis technology platform. The Company’s most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial (the “ADAPT trial”) for the treatment of metastatic renal cell carcinoma (“mRCC”). The Company is also developing a separate Arcelis-based product candidate, AGS-004, for the treatment of HIV, which is currently being evaluated in a clinical trial in combination with vorinostat aimed at HIV eradication in adult patients. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Accordingly, the statements do not include all information and footnotes required by U.S. GAAP for annual consolidated financial statements. In the opinion of management, such interim financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of financial position, results of operations and cash flows for such periods. The results for the three and six months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the year ended December 31, 2016 or future operating periods. The information included in these interim financial statements should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report on Form 10-Q and the consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015. The Company’s consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has incurred losses in each year since inception and as of June 30, 2016, had an accumulated deficit of $304.4 million. Also, as of June 30, 2016, the Company’s current assets totaled $37.3 million compared with current liabilities of $17.9 million, and the Company had cash, cash equivalents and short-term investments of $34.8 million. In light of the Company’s current operating plan, these factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements for the three and six months ended June 30, 2016 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. Until such time, if ever, as the Company can generate substantial product revenues, it expects to seek to raise additional funds through a combination of equity offerings, debt financings, government contracts, government and other third party grants or other third party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. There can be no assurance that the Company will be able to generate funds in these manners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition and the Company could be forced to delay, reduce, terminate or eliminate its product development programs. The condensed consolidated financial statements include the accounts of the Company and DC Bio Corp., the Company’s Canadian wholly-owned subsidiary, an unlimited liability corporation incorporated in the Province of Nova Scotia. Significant intercompany transactions and accounts have been eliminated. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant Accounting Policies There have been no material changes in our significant accounting policies as of and for the three and six months ended June 30, 2016, as compared with the significant accounting policies described in our Annual Report on Form 10-K for the year ended December 31, 2015. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less as of the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States, Canada and the European Union. The Company maintains cash in accounts which are in excess of federally insured limits. As of December 31, 2015 and June 30, 2016, $5,913,144 and $34,580,164, respectively, in cash and cash equivalents were uninsured. Restricted Cash The Company had restricted cash of $740,000 as of each of December 31, 2015 and June 30, 2016, which consists of funds maintained in a separate deposit account to secure a letter of credit issued by a bank to the landlord under a lease agreement for the Company’s new corporate headquarters and primary manufacturing facility (see Note 7). Recently Issued Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842) Leases In May 2015, the FASB issued a new standard which removes the requirement to categorize the investments for which fair value is measured using net asset value per share as a practical expedient for fair value within the fair value hierarchy. This standard is effective for the Company for reporting periods beginning after December 15, 2015 and is to be applied retrospectively; early adoption is permitted. The Company adopted this standard during the three months ended March 31, 2016. There was no impact on the Company’s consolidated financial statements. In April 2015, the FASB issued a new standard update which requires debt issuance costs to be presented in the consolidated balance sheet as a direct deduction from the associated debt liability. This standard became effective for the Company beginning on January 1, 2016 and is applied on a retrospective basis. As a result, deferred financing costs of $93,503 and $85,002 were reclassified to long-term debt as of December 31, 2015 and March 31, 2016, respectively. In August 2014, the FASB issued a new standard update that specifies the responsibility that an entity’s management has to evaluate whether there is substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for interim and annual periods beginning after December 15, 2016, and is not expected to have an effect on the Company’s consolidated financial statements. In May 2014, the FASB issued a new accounting standard update pertaining to accounting for revenue from contracts with customers. The new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. In July 2015, the FASB finalized a one-year delay in the effective date of this standard, which will now be effective for the Company beginning January 1, 2018, however early adoption is permitted any time after the original effective date, which for the Company is January 1, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.

Note 2 - Fair Value of Financia

Note 2 - Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Fair Value Disclosures [Text Block]	2. Fair Value of Financial Instruments The estimated fair values of all of the Company’s financial instruments, excluding long-term debt, approximate their carrying amounts in the consolidated balance sheets as of December 31, 2015 and June 30, 2016. As of December 31, 2015 and June 30, 2016, the Company held certain assets that are required to be measured at fair value on a recurring basis. These assets include money market funds included in cash equivalents and short-term investments in corporate debt securities. The Company’s short-term investments are classified as available-for-sale investments. As of June 30, 2016, the Company did not own any short-term investments. The valuation of these financial instruments uses a three tiered approach, which requires that fair value measurements be classified and disclosed in one of three tiers. These tiers are: Level 1, defined as quoted prices in active markets for identical assets or liabilities; Level 2, defined as valuations based on observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets, or other inputs that are observable or can be corroborated by observable input data; and Level 3, defined as valuations based on unobservable inputs reflecting the Company’s own assumptions, consistent with reasonably available assumptions made by other market participants. The Company’s Level 1 assets consist of money-market funds and restricted cash in a deposit account at a bank. The method used to estimate the fair value of the Level 1 assets is based on observable market data, as these money-market funds are publicly-traded. The Company’s Level 2 assets consist of short-term debt instruments in corporate debt securities valued using independent pricing services which normally derive security prices from recently reported trades for identical or similar securities, making adjustments based on significant observable transactions. As of each balance sheet date, observable market inputs may include trade information, broker or dealer quotes, bids, offers or a combination of these data sources. During the three and six months ended June 30, 2016, there were no transfers between Levels 1 and 2 assets. As of December 31, 2015 and June 30, 2016, these financial instruments and respective fair values have been classified as follows: Quoted Prices Significant Significant Balance as of Assets Money-market funds $ 5,589,684 $ — $ — $ 5,589,684 Corporate debt securities – short-term — 1,003,160 — 1,003,160 Restricted cash 740,000 740,000 Total assets at fair value $ 6,329,684 $ 1,003,160 $ — $ 7,332,844 Quoted Prices Significant Significant Balance as of Assets Money-market funds $ 343,841 $ — $ — $ 343,841 Restricted cash 740,000 740,000 Total assets at fair value $ 1,083,841 $ — $ — $ 1,083,841 The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and estimated fair value of money-market funds included in cash and cash equivalents, corporate debt securities included in short-term investments and restricted cash as of December 31, 2015 and June 30, 2016 were as follows: As of December 31, 2015 Amortized Cost Gross Gross Aggregate Money-market funds $ 5,589,684 $ — $ — $ 5,589,684 Corporate debt securities – short term 1,003,431 — (271 ) 1,003,160 Restricted cash 740,000 — — 740,000 $ 7,333,115 $ — $ (271 ) $ 7,332,844 As of June 30, 2016 Amortized Cost Gross Gross Aggregate Money-market funds $ 343,841 $ — $ — $ 343,841 Restricted cash 740,000 — — 740,000 $ 1,083,841 $ — $ — $ 1,083,841 The fair value of the Company’s debt was derived by evaluating the nature and terms of each note, considering the prevailing economic and market conditions as of each balance sheet date and based on the Level 2 valuation hierarchy of the fair value measurements standard using a present value methodology. The fair value of the Company’s debt as of December 31, 2015 was approximately $32.0 million compared with its carrying value of $32.4 million. The fair value of the Company’s debt as of June 30, 2016 was approximately $30.9 million compared with its carrying value of $31.3 million (see Note 5).

Note 3 - Property and Equipment

Note 3 - Property and Equipment	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	3. Property and Equipment Property and equipment consist of the following: December 31, 2015 June 30, 2016 Office furniture and equipment $ 681,954 $ 681,954 Computer equipment 970,689 1,099,033 Computer software 629,948 3,143,722 Laboratory equipment 5,916,539 5,908,068 Leasehold improvements 2,664,669 2,664,669 Asset related to facility lease obligation 7,630,660 7,640,660 Construction-in-progress 12,656,260 17,274,267 31,150,719 38,412,373 Less: Accumulated depreciation and amortization (8,844,335 ) (9,267,285 ) Property and equipment, net $ 22,306,384 $ 29,145,088 Assets related to the Company’s facility lease obligation and construction-in-progress were recognized primarily due to the Company being deemed to be the accounting owner of the facility being built to be the Company’s corporate headquarters and primary manufacturing facility during its construction period under build-to-suite lease accounting (see Note 7). As of December 31, 2015 and June 30, 2016, construction-in-progress included $880,334 and $1,730,885, respectively, of capitalized interest. Depreciation and amortization expense was as follows: Three months ended June 30, 2015 $ 181,530 Three months ended June 30, 2016 $ 237,996 Six months ended June 30, 2015 $ 347,962 Six months ended June 30, 2016 $ 439,738

Note 4 - Income Taxes

Note 4 - Income Taxes	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	4. Income Taxes The Company has incurred net operating losses since inception and is forecasting additional losses through December 31, 2016. Therefore, no U.S. federal, state or foreign income taxes are expected for 2016 and no provision for such taxes has been recorded as of June 30, 2016. Due to the Company’s history of losses since inception, there is not enough evidence at this time to support the conclusion that the Company will generate future income of a sufficient amount and nature to utilize the benefits of the Company’s net deferred tax assets. Accordingly, as of December 31, 2015 and June 30, 2016, the Company provided a full valuation allowance against its net deferred tax assets since as of that time, the Company could not assert that it was more likely than not that these deferred tax assets would be realized.

Note 5 - Notes Payable

Note 5 - Notes Payable	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Debt Disclosure [Text Block]	5. Notes Payable Notes payable consist of the following as of December 31, 2015 and June 30, 2016: December 31, June 30, Notes payable under the venture loan and security agreement, including accrued interest $ 25,265,451 $ 25,431,010 Less debt discount and debt issuance costs (495,229 ) (407,819 ) Notes payable under the venture loan and security agreement, net 24,770,222 25,023,191 Promissory note payable to Medinet, including accrued interest 7,489,565 6,228,635 Other notes payable 46,755 39,026 Total notes payable 32,306,542 31,290,852 Less current portion (1,578,284 ) (6,787,283 ) Long-term portion of notes payable $ 30,728,258 $ 24,503,569 Venture Loan Facility. The Company borrowed the first tranche of $12.5 million upon the closing of the Loan Facility in September 2014 and borrowed the second tranche of $12.5 million in August 2015. The per annum interest rate for each tranche is a floating rate equal to 9.25% plus the amount by which the one-month London Interbank Offered Rate (“LIBOR”) exceeds 0.50% (effectively a floating rate equal to 8.75% plus the one-month LIBOR Rate). The total per annum interest rate shall not exceed 10.75%. The Company incurred $449,796 in debt issuance costs in connection with the closing of the Loan Facility. Debt issuance costs are presented in the consolidated balance sheet as a direct deduction from the associated liability and amortized to interest expense over the terms of the related debt. The Company has agreed to repay the first tranche of $12.5 million on an interest-only basis monthly until September 30, 2016, followed by monthly payments of principal and accrued interest through the scheduled maturity date for the first tranche loan on September 30, 2018. In addition, a final payment for the first tranche loan equal to $625,000 will be due on September 30, 2018, or such earlier date specified in the Loan Agreement. The Company is recognizing the final payment of $625,000 as accrued interest over the expected life of the first tranche loan. The Company has agreed to repay the second tranche loan of $12.5 million in 18 monthly payments of interest only until February 7, 2017, followed by 24 monthly payments of principal and accrued interest through the scheduled maturity date for the second tranche loan on February 7, 2019. In addition, a final payment of $625,000 will be due on February 7, 2019, or such earlier date specified in the Loan Agreement. The Company is recognizing the final payment of $625,000 as accrued interest over the expected life of the second tranche loan. In addition, the Company has agreed that if the Company repays all or a portion of the loan prior to the applicable maturity date, it will pay the Lenders a prepayment penalty fee based on a percentage of the then outstanding principal balance, equal to 3% if the prepayment occurs on or before 24 months after the funding date, 2% if the prepayment occurs more than 24 months after, but on or before 36 months after, the funding date thereof, or 1% if the prepayment occurs more than 36 months after the funding date thereof. The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets other than its intellectual property. The Company also has agreed not to pledge or otherwise encumber its intellectual property assets, subject to certain exceptions. The Loan Agreement includes customary affirmative and restrictive covenants, but does not include any covenants to attain or maintain certain financial metrics, and also includes customary events of default, including payment defaults, breaches of covenants, change of control and a material adverse change default. Upon the occurrence of an event of default and following any applicable cure periods, a default interest rate of an additional 5% may be applied to the outstanding loan balances, and the Lenders may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. In connection with the Loan Agreement, the Company issued to the Lenders and their affiliates warrants to purchase a total of 82,780 shares of the Company’s common stock at a per share exercise price of $9.06 (the “Warrants”). Upon the Company’s satisfaction of the conditions precedent to the making of the second tranche loan, the Warrants became exercisable in full. The Warrants will terminate on September 29, 2021 or such earlier date as specified in the Warrants. As of September 29, 2014, the Company recorded a debt discount of $338,673 equal to the value of these Warrants. This debt discount is offset against the note payable balance and included in additional paid-in capital on the Company's consolidated balance sheet. Medinet Loan. During the year ended December 31, 2015, the Company recognized a $1.0 million milestone payment as deferred revenue under the Medinet license agreement and reduced the related note payable by $0.8 million and the deferred liability by $0.2 million. As of December 31, 2015, the amount of the note payable was $7.5 million, including $1.3 million of accrued interest. During the three months ended June 30, 2016, the Company recognized a $2.0 million milestone payment as deferred revenue under this license agreement and reduced the related note payable by $1.5 million and the deferred liability by $0.5 million. As of June 30, 2016, the amount of the note payable was $6.2 million, including $1.6 million of accrued interest. As of December 31, 2015 and June 30, 2016, the total deferred liability associated with the Medinet note was $3.8 million and $5.3 million, respectively (see Note 11). Other Notes.

Note 6 - Manufacturing Research

Note 6 - Manufacturing Research and Development Obligation	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Research, Development, and Computer Software Disclosure [Text Block]	6. Manufacturing Research and Development Obligation In October 2014, the Company entered into a development agreement (the “Invetech Development Agreement”) with Invetech Pty Ltd (“Invetech”). The Invetech Development Agreement supersedes and replaces the development agreement entered into by the parties in July 2005. Under the Invetech Development Agreement, Invetech will continue to develop and provide prototypes of the automated production system to be used for the manufacture of the Company’s Arcelis-based products (the “Production Systems”). Development services will be performed on a proposal by proposal basis. Invetech has agreed to defer 30% of its fees, but such deferral will not exceed $5.0 million. Deferred fees (plus interest of 7% per annum) would become payable either, at the Company’s option, in a lump sum within 90 days of the “Sunset Date Trigger Event” or pursuant to an installment plan (either in four installments payable within the first year or eight installments payable within the first two years after the “Sunset Date Trigger Event”). The “Sunset Date Trigger Event” is December 31, 2016. Invetech is entitled to a 10% bonus payment if the ADAPT trial is closed early indicating positive efficacy or if the ADAPT trial meets the primary endpoint of overall survival and the 100% of events analysis indicates positive efficacy, and if Invetech has timely completed all activities up to the time the ADAPT trial is stopped. As of December 31, 2015, the Company recorded this manufacturing research and development obligation on its consolidated balance sheet at $7.8 million, representing $5.2 million in deferred fees, $2.3 million in estimated bonus payments and $0.3 million in accrued interest. As of June 30, 2016, the Company recorded this manufacturing research and development obligation on its consolidated balance sheet at $8.0 million, representing $5.2 million in deferred fees, $2.3 million in estimated bonus payments and $0.5 million in accrued interest, of which $2.1 million is included in current liabilities as the current portion of the obligation. The Invetech Development Agreement requires the parties to discuss in good faith Invetech’s supply of Production Systems for use in manufacturing commercial product. The Company has an obligation to purchase $25.0 million worth of Production Systems, components, subsystems and spare parts for commercial use. Once that obligation has been satisfied, the Company has the right to have a third party supply Production Systems for use in manufacturing commercial product provided that Invetech has a right of first refusal with respect to any offer by a third party and the Company may not accept an offer from a third party unless that offer is at a price that is less than that offered by Invetech and otherwise under substantially the same or better terms. The Company will own all intellectual property arising from the development services (with the exception of existing Invetech intellectual property incorporated therein under which the Company will have a license). The Invetech Development Agreement will continue until the completion of the development of the Production Systems. The Invetech Development Agreement can be terminated early by either party because of a technical failure or by the Company without cause.

Note 7 - Facility Lease Obligat

Note 7 - Facility Lease Obligation	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	7. Facility Lease Obligation In August 2014, the Company entered into a Lease Agreement (the “Lease Agreement”) with TKC LXXII, LLC, a North Carolina limited liability company (“TKC”). Under the Lease Agreement, the Company agreed to lease certain land and an approximately 125,000 square-foot building to be constructed in Durham County, North Carolina. The Company intended this facility to be built to house the Company’s corporate headquarters and primary manufacturing facility. The lease for the current facility expires in November 2016. The shell of the new facility was constructed on a build-to-suit basis by TKC in accordance with agreed upon specifications and plans as set forth in the Lease Agreement and at the expense of TKC, other than those costs resulting from changes requested by the Company, for which the Company has paid $1.7 million as of June 30, 2016. The term of the Lease Agreement is 10 years from the commencement date of July 1, 2015. The Company has an option to extend the Lease Agreement by six five-year renewal terms. Current rent payments in the second year are $47,972 per month, subject to certain fixed increases over the course of the term as set forth in the Lease Agreement and adjustment based on the Company’s use of certain amounts allocated for upfitting the interior of the facility. The Lease Agreement required the Company to provide TKC with a letter of credit. The Company provided the bank that issued the letter of credit on its behalf a security deposit of $1,325,000 to guarantee the letter of credit. In accordance with the Lease Agreement, this deposit was reduced to $740,000 as of December 31, 2015 under a purchase and sale agreement with TKC. The deposit is recorded as restricted cash as of December 31, 2015 and June 30, 2016 on the Company’s consolidated balance sheets. Under the Lease Agreement, the Company is involved in the construction of the building. To the extent the Company is involved with the structural improvements of the construction project or takes construction risk prior to the commencement of a lease, ASC 840-40-05-5 requires for accounting purposes that the Company be considered the owner of this project during the construction period. Therefore, the Company recorded an asset in property and equipment, net on the Company’s consolidated balance sheets for the cost of the Company’s portion of the building plus the amount of estimated structural construction costs incurred by TKC and the Company as of the applicable balance sheet date. The Company recorded a corresponding facility lease obligation on its consolidated balance sheets representing the amounts paid by TKC. The initial recording of these assets and liabilities is classified as non-cash investing and financing items, respectively, for purposes of the Company’s consolidated statements of cash flows. The Company recorded an asset related to the facility lease obligation included in property and equipment of $7.6 million as of each of December 31, 2015 and June 30, 2016. The facility lease obligation on the Company’s consolidated balance sheet is $7.2 million as of each of December 31, 2015 and June 30, 2016. Under the Lease Agreement, the Company had an option to purchase the property. In February 2015, the Company exercised this purchase option and entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with TKC. The purchase price to be paid by the Company at closing is $7.4 million plus the amount of any additional costs incurred by TKC as a result of changes requested by the Company, for which the Company has paid $1.7 million as of June 30, 2016, and the amount of any improvement allowances advanced to the Company by TKC prior to the closing. Under the terms of the Purchase Agreement, the Company had until February 16, 2016 to consummate the purchase of the property. However on July 1, 2016, TKC and the Company amended the Purchase Agreement to extend the period for purchasing the property until September 23, 2016. If the Company purchases the property, the Lease Agreement will terminate upon the closing.

Note 8 - Stockholders' (Deficit

Note 8 - Stockholders' (Deficit) Equity	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	8. Stockholders’ (Deficit) Equity Issuance of Common Stock in the First Half of 2016 PIPE Financing On March 4, 2016, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company agreed to issue and sell an aggregate of up to $60 million of the Company’s common stock (the “Shares”) and warrants to purchase shares of common stock (the “Warrants”) in a private placement (the “PIPE Financing”). Investors participating in the PIPE Financing included Pharmstandard, ForArgos B.V., Tianyi Lummy International Holdings Group Ltd. (“Tianyi Lummy”), China BioPharma Capital I, L.P. (“China BioPharma”), TVM V Life Science Ventures GmbH & Co. KG and Wasatch Funds Trust. Andrei Petrov, Igor Krol, Hubert Birner and Sander van Deventer (collectively, the “Investor Directors”), who are members of the Company’s board of directors, are affiliated with certain of the Investors. The PIPE Financing was to take place in up to three tranches. Under the Securities Purchase Agreement, at the initial closing, which occurred on March 14, 2016, the Company sold and the Investors purchased for a total purchase price of $19,882,915 a total of 3,652,430 Shares and Warrants to purchase a total of 2,739,323 shares of common stock (0.75 shares of common stock for each Share purchased), based on a purchase price per Share and accompanying Warrant equal to $5.44375 (the “Purchase Price”). At the second closing, which occurred on June 29, 2016, the Company sold and the Investors purchased for a total purchase price of $29,824,520 a total of 5,478,672 Shares and Warrants to purchase a total of 4,109,005 shares of common stock (0.75 shares of common stock for each Share purchased), based on a purchase price per Share and accompanying Warrant equal to the Purchase Price. The closing of the second tranche was triggered by the recommendation from the Company’s independent data monitoring committee (the “IDMC”) that the Company continue the trial for the treatment of metastatic renal cell carcinoma based on the results of the IDMC’s scheduled interim data review. The Warrants have an exercise price of $5.35 per share, expire on the fifth anniversary of the date of issuance and have other terms described below under “Warrants.” Under the Securities Purchase Agreement, Pharmstandard International S.A. (“Pharmstandard”) agreed that, at the Company’s option following the satisfaction of certain conditions, it could be required to purchase at a third closing up to $10,292,563 of Shares (without Warrants). The dollar amount of Shares to be purchased by Pharmstandard at the third closing was subject to reduction on a dollar-for-dollar basis for certain cash amounts raised by the Company after the initial closing through equity or debt financings or collaborations. The net proceeds received from the sale of common stock and accompanying warrants in the Company’s follow-on public offering that closed on August 2, 2016 (see Note 13) reduced in full the dollar amount committed to be purchased in the third tranche and as a result the Company has no further ability to effect the closing of, and Pharmstandard has no further obligation to purchase Shares in, the third tranche of the PIPE Financing. Under the Securities Purchase Agreement, Pharmstandard has also agreed that to the extent that and for so long as the total voting power of voting securities of the Company beneficially owned by Pharmstandard and its affiliates and any other Persons whose beneficial ownership of the Company’s common stock would be aggregated with Pharmstandard for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, exceeds 33% of the voting power of the total number of voting securities of the Company then outstanding, in any election of directors and in any other matter submitted to a general vote of the stockholders of the Company (whether taken at an annual or special meeting of stockholders or by written action) Pharmstandard shall and shall cause its affiliates and such other persons whose beneficial ownership of the Company’s common stock would be aggregated with Pharmstandard for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, to vote such number of voting securities of the Company which exceed 33% of the voting power of the total number of voting securities of the Company then outstanding in the same manner as and in the same proportion to the votes cast on the matter by the other holders of voting securities of the Company. The Company agreed to pay at each closing the legal expenses of the Investors and the legal expenses of the Investors incurred in connection with the resale registration obligations of the Company set forth in the Registration Rights Agreement; provided, however, that the Company had no obligation to pay more than a total of $140,000 with respect to such expenses. The Company has granted the Investors, and the Investors have granted the Company, indemnification rights with respect to its or their representations, warranties, covenants and agreements under the Securities Purchase Agreement. Warrants The Warrants issued at the first closing and second closing are exercisable for shares of the Company’s common stock at an exercise price of $5.35 per share on or prior to the fifth anniversary of the date of issuance, are immediately exercisable, and are exercisable for cash or by cashless exercise in certain limited circumstances. Registration Rights Agreement On March 4, 2016, in connection with entering into the Securities Purchase Agreement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Investors, pursuant to which the Company agreed to register for resale the Shares and the shares of the Company’s common stock issued upon exercise of the Warrants (the “Warrant Shares,” and together with the Shares, the “Registrable Securities”). Under the Registration Rights Agreement, the Company agreed to use its best efforts to file a registration statement after each closing covering the Shares and the Warrant Shares underlying the Warrants sold at such closing, as applicable, and to use its best efforts to keep such registration statement effective until the date the Shares and Warrant Shares covered by such registration statement have been sold or may be sold pursuant to Rule 144 without restriction. In the event a registration statement has not been filed within 60 days of the initial closing and within 30 days of each of the second and third closings, if any, (in each case subject to extension under certain circumstances), then the Company has agreed to make pro rata payments to each Investor that participated in such closing as liquidated damages in an amount equal to 1% of the aggregate amount invested by each such Investor in such closing per 30-day period or pro rata for any portion thereof during which no such registration statement is filed with respect to the applicable Registrable Securities. Moreover, in the event that (i) a registration statement covering Registrable Securities issued at a certain closing is not declared effective by the SEC by the 120 th th The Company has granted the Investors, and the Investors have granted to the Company, customary indemnification rights in connection with the registration statements. At-the-market Offering In May 2015, the Company entered into a sales agreement, or the Sales Agreement, with Cowen & Company, LLC, or Cowen, pursuant to which the Company may issue and sell shares of the Company’s common stock from time to time having an aggregate offering price of up to $30 million through Cowen, acting as the Company’s agent. Sales of the Company’s common stock through Cowen may be made by any method permitted that is deemed an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on or through the Nasdaq Global Market, sales made to or through a market maker other than on an exchange or otherwise, in negotiated transactions at market prices, and/or any other method permitted by law. Cowen is not required to sell any specific amount, but acts as the Company’s sales agent using commercially reasonable efforts consistent with its normal trading and sales practices. Shares sold pursuant to the Sales Agreement have been sold pursuant to a shelf registration statement, which became effective on May 14, 2015. Under the Sales Agreement, the Company has agreed to pay Cowen a commission of up to 3% of the gross proceeds of any sales made pursuant to the Sales Agreement. During the three months ended June 30, 2016, the Company sold 800,392 shares of common stock pursuant to the Sales Agreement, resulting in proceeds of $5.1 million, net of commissions and issuance costs. As of August 8, 2016, the Company has sold approximately 873,000 shares of common stock pursuant to the Sales Agreement, resulting in proceeds of approximately $5.5 million, net of commissions and issuance costs. Other Common Stock Issued in the First Half of 2016 In lieu of paying certain annual cash bonuses for 2015, in January 2016 the Company granted restricted stock awards to certain of its executive officers and employees. The number of shares granted to each executive officer and employee was calculated by dividing the amount of the 2015 annual cash bonus that would otherwise have been paid to such executive officer or employee by the closing price of the Company’s common stock on January 8, 2016 of $2.24 per share. A total of 296,936 shares of restricted common stock with a value of $665,137 were issued. Each of the restricted stock awards is subject to a lapsing right of repurchase in the Company’s favor, which right will lapse with respect to 100% of the underlying shares of each award on November 20, 2016, assuming such executive or employee is still providing services to the Company on such date. For 2016, the Company’s board of directors determined that each non-employee director will receive shares of the Company’s common stock under the Company’s 2014 stock incentive plan in lieu of cash board fees on the last day of each calendar quarter in 2016. The number of shares to be granted to each non-employee director on a quarterly basis shall be that number of whole shares of the Company’s common stock equal to the dollar amount of such director’s fees for a given calendar quarter divided by the closing share price of the Company’s common stock on the last trading day of such calendar quarter. During the three and six months ended June 30, 2016, the Company issued 11,066 and 23,563 shares, respectively, of its common stock as board compensation to non-employee directors in lieu of $67,835 and $147,815,respectively, in cash board fees and is included in general and administrative expenses. During the three and six months ended June 30, 2016, the Company issued share-based expense from restricted stock to employees and a consultant of $43,229; $38,090 is included in general and administrative expenses and $5,139 is included in research and development expenses.

Note 9 - Stock Options and Warr

Note 9 - Stock Options and Warrants	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	9. Stock Options and Warrants 2014 Stock Incentive Plan and 2014 Employee Stock Purchase Plan In January 2014, the Company’s board of directors and stockholders approved, effective upon the closing of the Company’s initial public offering, the 2014 Stock Incentive Plan (the “2014 Plan”). Under the 2014 Plan, the Company may grant incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards for the purchase of that number of shares of common stock equal to the sum of 1,951,182 shares, plus such number of shares, up to 357,841 shares, as is equal to the sum of the number of shares reserved for issuance under the Company’s 2008 Stock Incentive Plan (the “2008 Plan”) that remained available for grant under the 2008 Plan immediately prior to the closing of the Company’s initial public offering on February 12, 2014 (381,250 shares) and the number of shares subject to outstanding awards under the 2008 Plan that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right, plus an annual increase, to be added on the first day of each fiscal year from January 1, 2015 through January 1, 2024, equal to the lowest of 2,309,023 shares of common stock, 4% of the number of the Company’s outstanding shares on the first day of each such fiscal year and an amount determined by the Company’s board of directors. Also in January 2014, the Company’s board of directors and stockholders approved, effective upon the closing of the Company’s initial public offering, a 2014 Employee Stock Purchase Plan (the “2014 ESPP”). Under the 2014 ESPP, on the offering commencement date of each plan period (the “Purchase Plan Period”), the Company will grant to each eligible employee who is then a participant in the 2014 ESPP an option to purchase shares of common stock. The employee may authorize up to a maximum of 10% of his or her base pay to be deducted by the Company during each Purchase Plan Period. Each employee who continues to be a participant in the 2014 ESPP on the last business day of the Purchase Plan Period is deemed to have exercised the option, to the extent of accumulated payroll deductions within the 2014 ESPP ownership limits. Under the terms of the 2014 ESPP, the option exercise price shall be determined by the Company’s board of directors for each Purchase Plan Period and the option exercise price will be at least 85% of the applicable closing price of the common stock. The option exercise price will be 85% of the lower of the Company’s closing stock price on the first and last business day of each Purchase Plan Period. The Company’s first Purchase Plan Period commenced on September 2, 2014 and ended on February 27, 2015. For the first Purchase Plan Period, 13,054 shares were purchased with employee withholdings at an option exercise price based upon 85% of the lower of the closing price at the beginning of the first Purchase Plan Period of $9.83 and the closing price on February 27, 2015 of $9.02, resulting in the recognition of stock-based compensation expense of $54,508. The Company’s second Purchase Plan Period commenced on March 2, 2015 and ended on August 31, 2015. For the second Purchase Plan Period, 20,301 shares were purchased with employee withholdings at an option exercise price based upon 85% of the lower of the closing price at the beginning of the second Purchase Plan Period of $9.02 and the closing price on August 31, 2015 of $6.21, resulting in the recognition of stock-based compensation expense of $72,800. The Company’s third Purchase Plan Period commenced on September 1, 2015 and ended on February 29, 2016. For the third Purchase Plan Period, 36,290 shares were purchased with employee withholdings at an option exercise price based upon 85% of the lower of the closing price at the beginning of the third Purchase Plan Period of $6.24 and the closing price of $4.44 on February 29, 2016, resulting in the recognition of stock-based compensation expense of $107,455. The Company’s fourth Purchase Plan Period commenced on March 1, 2016 and will end on August 31, 2016. Based upon 85% of the lower of the closing price at the beginning of the fourth Purchase Plan Period of $4.91 and the closing price of $6.13 on June 30, 2016, stock-based compensation expense of $51,371 was recognized. Upon the exercise of stock options, vesting of other awards and purchase of shares through the 2014 ESPP or under the 2014 Plan, the Company issues new shares of common stock. All awards granted under the 2014 Plan that are canceled prior to vesting or expire unexercised are returned to the approved pool of reserved shares under the 2014 Plan and made available for future grants. As of June 30, 2016, there were 774,189 shares of common stock remaining available for future issuance under the 2014 Plan and 276,708 shares of common stock remaining available for future issuance under the 2014 ESPP. The Company recorded the following stock-based compensation expense excluding restricted stock awards: Three Months Ended June 30, Six Months Ended June 30, 2015 2016 2015 2016 Research and development $ 401,826 $ 997,090 $ 808,017 $ 1,434,285 General and administrative 496,249 637,083 1,004,573 1,073,111 Total stock-based compensation expense $ 898,075 $ 1,634,173 $ 1,812,590 $ 2,507,396 Allocations to research and development and general and administrative expenses are based upon the department to which the associated employee reported. No related tax benefits of the stock-based compensation expense have been recognized. Stock-based payments issued to nonemployees are recorded at their fair values, and are periodically revalued as the equity instruments vest and are recognized as expense over the related service period. During the three months ended June 30, 2016, modifications were made to certain stock option grants that accelerated the vesting of such grants to 18 terminated employees resulting in an increase to stock-based compensation expense of $0.6 million. During the three months ended June 30, 2015, the Company granted options to employees to purchase a total of 510,650 shares of the Company’s common stock at exercise prices ranging from $7.05 to $8.46 per share, which in each instance was the closing price of the Company’s common stock on the grant date. During the three months ended June 30, 2016, the Company granted options to employees to purchase a total of 899,456 shares of the Company’s common stock at exercise prices ranging from $5.71 to $10.97 per share, which in each instance was the closing price of the Company’s common stock on the grant date, except for 565,000 options granted to the Company’s executive committee employees which have an exercise price of $7.41 compared with the $5.95 closing price of the Company’s common stock on the grant date. During the six months ended June 30, 2015, the Company granted options to employees and non-employee directors to purchase a total of 622,300 shares of the Company’s common stock at exercise prices ranging from $7.05 to $9.01 per share, which in each instance was the closing price of the Company’s common stock on the grant date. During the six months ended June 30, 2016, the Company granted options to employees to purchase a total of 1,210,106 shares of the Company’s common stock at exercise prices ranging from $2.16 to $10.97 per share, which in each instance was the closing price of the Company’s common stock on the grant date, except for 565,000 options granted to the Company’s executive committee employees which have an exercise price of $7.41 compared with the $5.95 closing price of the Company’s common stock on the grant date. The following table summarizes the Company’s stock option activity during the six months ended June 30, 2016: Number of Weighted Weighted Outstanding as of December 31, 2015 3,318,541 $ 6.24 Granted 1,210,106 $ 5.72 Exercised (20,995 ) $ 6.32 Cancelled (85,566 ) $ 7.01 Outstanding as of June 30, 2016 4,422,086 $ 6.08 8.15 Exercisable as of June 30, 2016 1,943,789 $ 5.93 7.08 Vested and expected to vest as of June 30, 2016 4,231,093 $ 6.08 8.11 Valuation Assumptions for Stock Option Plans and Employee Stock Purchase Plan The employee stock-based compensation expense recognized was determined using the Black-Scholes option valuation model. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The weighted average assumptions used were as follows for the periods indicated: Stock Option Plan Employee Stock Purchase Plan Six Months Ended June 30, Six Months Ended June 30, 2015 2016 2015 2016 Risk-free interest rate 2.07 % 1.53 % 0.07 % 0.5 % Dividend yield 0 % 0 % 0 % 0 % Expected option term (in years) 7 7 0.5 0.5 Volatility 86 % 82 % 45 % 141 % Warrants As discussed in Note 8, regarding the PIPE Financing, on March 14, 2016, the Company sold and the Investors purchased for a total purchase price of $19,882,915 a total of 3,652,430 Shares and Warrants to purchase a total of 2,739,323 shares of common stock at a per share exercise price of $5.35. These Warrants will terminate on March 14, 2021 or such earlier date as specified in the warrants. Additionally, on June 29, 2016, the Company sold and the Investors purchased for a total purchase price of $29,824,520 a total of 5,478,672 Shares and Warrants to purchase a total of 4,109,005 shares of common stock at a per share exercise price of $5.35. These Warrants will terminate on June 29, 2021 or such earlier date as specified in the warrants. In June 2016, Warrants were exercised to purchase 56,062 shares of common stock for proceeds of $299,932 to the Company. As discussed in Note 5 regarding the Company’s notes payable, in connection with the Loan Agreement, the Company issued to the Lenders and their affiliates warrants to purchase a total of 82,780 shares of common stock at a per share exercise price of $9.06. Upon the Company’s satisfaction of the conditions precedent to the making of the second tranche loan, the warrants became exercisable in full. The warrants will terminate on September 29, 2021 or such earlier date as specified in the warrants. Outstanding warrants to purchase the Company’s common stock as of June 30, 2016 were as follows: Type of Warrant Number of Shares Exercise Price Expiration Common stock 1 $ 23,894.34 7/13/16 Common stock 82,780 $ 9.06 9/29/21 Common stock 2,683,261 $ 5.35 3/14/21 Common stock 4,109,005 $ 5.35 6/29/21 In November 2013, the Company entered into an agreement with Pharmstandard under which Pharmstandard purchased additional shares of the Company’s Series E preferred stock. Upon the closing of the Company’s initial public offering, all of the outstanding shares of redeemable convertible preferred stock automatically converted into 13,188,251 shares of the Company’s common stock. Under this agreement, the Company agreed to enter into a manufacturing rights agreement for the European market with Pharmstandard and that the manufacturing rights agreement would provide for the issuance of warrants to Pharmstandard to purchase 499,788 shares of the Company’s common stock at an exercise price of $5.82 per share. As of June 30, 2016, the Company had not entered into this manufacturing rights agreement or issued such warrants.

Note 10 - Revenue and Concentra

Note 10 - Revenue and Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	10. Revenue and Concentration of Credit Risk In September 2006, the Company entered into a multi-year research contract with the National Institutes of Health (“NIH”) and the National Institute of Allergy and Infectious Diseases (“NIAID”) to design, develop and clinically test an autologous HIV immunotherapy capable of eliciting therapeutic immune responses. The Company is using funds from this contract to develop AGS-004. Under this contract, as amended, the NIH and NIAID have committed to fund up to a total of $39.8 million, including reimbursement of direct expenses and allocated overhead and general and administrative expenses of up to $38.4 million and payment of other specified amounts totaling up to $1.4 million upon the Company’s achievement of specified development milestones. Since September 2010, the Company has received reimbursement of its allocated overhead and general and administrative expenses at provisional indirect cost rates equal to negotiated provisional indirect cost rates agreed to with the NIH and NIAID in September 2010. These provisional indirect cost rates are subject to adjustment based on the Company’s actual costs pursuant to the agreement with the NIH and NIAID. This commitment originally extended until May 2013. The Company agreed to an additional modification of the Company’s contract with the NIH and NIAID under which the NIH and NIAID agreed to increase their funding commitment to the Company by an additional $5.4 million in connection with the extension of the contract from May 2013 to September 2015. Additionally, a contract modification for a $0.5 million increase was agreed to by the NIH on September 18, 2014 to cover a portion of the manufacturing costs of the planned Phase 2 clinical trial of AGS-004 for long-term viral control in pediatric patients. This modification extended the NIH and NIAID’s commitment under the contract to July 2016. On June 29, 2016, a contract modification was agreed to that extended the NIH and NIAID’s commitment under the contract to July 31, 2018. The Company has agreed to a statement of work under the contract, and is obligated to furnish all the services, qualified personnel, material, equipment, and facilities not otherwise provided by the U.S. government, needed to perform the statement of work. The Company recognizes revenue from reimbursements earned in connection with the contract as reimbursable costs are incurred and recognizes revenues from the achievement of milestones under the NIH and NIAID contract upon the accomplishment of any such milestone. For the three months ended June 30, 2015 and 2016, the Company recorded revenue under this agreement of $79,891 and $461,143, respectively. For the six months ended June 30, 2015 and 2016, the Company recorded revenue under this agreement of $243,606 and $552,572, respectively. The Company has recorded total revenue of $37.7 million through June 30, 2016 under the NIH and NIAID agreement. As of June 30, 2016, there was up to $2.1 million of potential revenue remaining to be earned under the agreement with the NIH and NIAID. As of December 31, 2015 and June 30, 2016, the Company recorded a receivable from the NIH and NIAID of $73,818 and $461,143, respectively. The concentration of credit risk is equal to the outstanding accounts receivable and such risk is subject to the credit worthiness of the NIH and NIAID. There have been no credit losses under this arrangement.

Note 11 - Collaboration Agreeme

Note 11 - Collaboration Agreements	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Long-term Contracts or Programs Disclosure [Text Block]	11. Collaboration Agreements Pharmstandard License Agreement In August 2013, Pharmstandard purchased shares of the Company’s series E preferred stock. Concurrently with such purchase, the Company entered into an exclusive royalty-bearing license agreement with Pharmstandard. Under this license agreement, the Company granted Pharmstandard and its affiliates a license, with the right to sublicense, develop, manufacture and commercialize AGS-003 and other products for the treatment of human diseases, which are developed by Pharmstandard using the Company’s individualized immunotherapy platform, in the Russian Federation, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine and Uzbekistan, which the Company refers to as the Pharmstandard Territory. The Company also provided Pharmstandard with a right of first negotiation for development and commercialization rights in the Pharmstandard Territory to specified additional products the Company may develop. Under the terms of the license agreement, Pharmstandard licensed the Company rights to clinical data generated by Pharmstandard under the agreement and granted the Company an option to obtain an exclusive license outside of the Pharmstandard Territory to develop and commercialize improvements to the Company’s Arcelis technology generated by Pharmstandard under the agreement, a non-exclusive worldwide royalty-free license to Pharmstandard improvements to manufacture products using the Company’s Arcelis technology and a license to specified follow-on licensed products generated by Pharmstandard outside of the Pharmstandard Territory, each on terms to be negotiated upon the Company’s request for a license. In addition, Pharmstandard agreed to pay the Company pass-through royalties on net sales of all licensed products in the low single digits until it has generated a specified amount of aggregate net sales. Once the net sales threshold is achieved, Pharmstandard will pay the Company royalties on net sales of specified licensed products, including AGS-003, in the low double digits below 20%. These royalty obligations last until the later of the expiration of specified licensed patent rights in a country or the twelfth anniversary of the first commercial sale in such country on a country by country basis and no further royalties on specified other licensed products. After the net sales threshold is achieved, Pharmstandard has the right to offset a portion of the royalties Pharmstandard pays to third parties for licenses to necessary third party intellectual property against the royalties that Pharmstandard pays to the Company. The agreement will terminate upon expiration of the royalty term, upon which all licenses will become fully paid-up perpetual exclusive licenses. Either party may terminate the agreement for the other party’s uncured material breach or if specified conditions occur relating to the other party’s insolvency or bankruptcy and the Company may terminate the agreement if Pharmstandard challenges or assists a third party in challenging specified patent rights of ours. If Pharmstandard terminates the agreement upon the Company’s material breach or bankruptcy, Pharmstandard is entitled to terminate the Company’s licenses to improvements generated by Pharmstandard, upon which the Company may come to rely for the development and commercialization of AGS-003 and other licensed products outside of the Pharmstandard Territory, and to retain its licenses from the Company and to pay the Company substantially reduced royalty payments following such termination. In November 2013, the Company entered into an agreement with Pharmstandard under which Pharmstandard purchased additional shares of the Company’s series E preferred stock. Under this agreement, the Company agreed to enter into a manufacturing rights agreement for the European market with Pharmstandard and that the manufacturing rights agreement would provide for the issuance of warrants to Pharmstandard to purchase 499,788 shares of the Company’s common stock at an exercise price of $5.82 per share. The Company has not entered into this manufacturing rights agreement or issued the warrants. All outstanding shares of the Company’s preferred stock converted into shares of the Company’s common stock upon the closing of its initial public offering in February 2014. Green Cross License Agreement In July 2013, the Company entered into an exclusive royalty-bearing license agreement with Green Cross Corp. ("Green Cross"). Under this agreement, the Company granted Green Cross a license to develop, manufacture and commercialize AGS-003 for mRCC in South Korea. The Company also provided Green Cross with a right of first negotiation for development and commercialization rights in South Korea to specified additional products the Company may develop. Under the terms of the license, Green Cross has agreed to pay the Company $500,000 upon the initial submission of an application for regulatory approval of a licensed product in South Korea, $500,000 upon the initial regulatory approval of a licensed product in South Korea and royalties ranging from the mid-single digits to low double digits below 20% on net sales until the fifteenth anniversary of the first commercial sale in South Korea. In addition, Green Cross has granted the Company an exclusive royalty free license to develop and commercialize all Green Cross improvements to the Company’s licensed intellectual property in the rest of the world, excluding South Korea, except that, as to such improvements for which Green Cross makes a significant financial investment and that generate significant commercial benefit in the rest of the world, the Company is required to negotiate in good faith a reasonable royalty that the Company will be obligated to pay to Green Cross for such license. Under the terms of the agreement, the Company is required to continue to develop and to use commercially reasonable efforts to obtain regulatory approval for AGS-003 in the United States. The agreement will terminate upon expiration of the royalty term, which is 15 years from the first commercial sale, upon which all licenses will become fully paid up perpetual non-exclusive licenses. Either party may terminate the agreement for the other party’s uncured material breach or if specified conditions occur relating to the other party’s insolvency or bankruptcy and the Company may terminate the agreement if Green Cross challenges or assists a third party in challenging specified patent rights of ours. If Green Cross terminates the agreement upon the Company’s material breach or bankruptcy, Green Cross is entitled to terminate the Company’s licenses to improvements and retain its licenses from the Company and to pay the Company substantially reduced milestone and royalty payments following such termination. Medinet License Agreement In December 2013, the Company entered into a license agreement with Medinet Co., Ltd. This agreement was subsequently novated, amended and restated among the Company, Medinet Co., Ltd. and MEDcell Co., Ltd. in October 2014. Pursuant to the novation, Medinet Co., Ltd. assigned and transferred all of its rights and obligations under the original license agreement, including the rights to receive payments under the $9.0 million note in favor of Medinet Co., Ltd., to MEDcell Co., Ltd. without any substantive change in the underlying rights or obligations. Medinet Co., Ltd. and MEDcell Co., Ltd. together are referred to herein as “Medinet.” Under this agreement, the Company granted Medinet an exclusive, royalty-free license to manufacture in Japan AGS-003 and other products using the Company’s Arcelis technology solely for the purpose of the development and commercialization of AGS-003 and these other products for the treatment of mRCC. The Company refers to this license as the manufacturing license. In addition, under this agreement, the Company granted Medinet an option to acquire a nonexclusive, royalty-bearing license under the Company’s Arcelis technology to sell in Japan AGS-003 and other products for the treatment of mRCC. The Company refers to the option as the sale option and the license as the sale license. This option expired on April 30, 2016. As a result, Medinet may only manufacture AGS-003 and these other products for the Company or its designee. The Company and Medinet have agreed to negotiate in good faith a supply agreement under which Medinet would supply the Company or its designee with AGS-003 and these other products for development and sale for the treatment of mRCC in Japan. During the term of the manufacturing license, the Company may not manufacture AGS-003 or these other products for the Company or any designee for development or sale for the treatment of mRCC in Japan. In consideration for the manufacturing license, Medinet paid the Company $1.0 million. Medinet also loaned the Company $9.0 million in connection with the Company entering into the agreement. The Company has agreed to use these funds in the development and manufacturing of AGS-003 and the other products. Medinet also agreed to pay the Company milestone payments of up to a total of $9.0 million upon the achievement of developmental and regulatory milestones and $5.0 million upon the achievement of a sales milestone related to AGS-003 and these products. Under the terms of the note and the manufacturing license agreement, any milestone payments related to the developmental and regulatory milestones that become due will be applied first to the repayment of the loan. The first milestone with a $1.0 million payment was achieved in July 2015 and the second milestone with a $2.0 million payment was achieved in June 2016, reducing the outstanding principal of the loan as of June 30, 2016 to $6.0 million. In December 2013, in connection with the manufacturing license agreement with Medinet, the Company borrowed $9.0 million pursuant to an unsecured promissory note that bears interest at a rate of 3.0% per annum. The principal and interest under the note are due and payable on December 31, 2018. The Company has the right to prepay the loan at any time. If the Company has not repaid the loan by December 31, 2018, then the Company has agreed to grant to Medinet a non-exclusive, royalty-bearing license to make and sell Arcelis products in Japan for the treatment of cancer. In such event, the amounts owing under the loan as of December 31, 2018 may constitute pre-paid royalties under the license or would be due and payable. Royalties under this license would be paid until the expiration of the licensed patent rights in Japan at a rate to be negotiated. If the Company and Medinet cannot agree on the royalty rate, the Company and Medinet have agreed to submit the matter to arbitration. The Company recorded the initial $1.0 million payment from Medinet as a deferred liability. In addition, because the $9.0 million promissory note was issued at a below market interest rate, the Company allocated the proceeds of the loan between the manufacturing license agreement and the debt at the time of issuance. Accordingly, as of December 31, 2013, the date of borrowing, the Company recorded $6.9 million to notes payable, based upon an effective interest rate of 8.0%, and $2.1 million as a deferred liability. During the year ended December 31, 2015, the Company recognized a $1.0 million milestone payment as deferred revenue under the license agreement and reduced the related note payable by $0.8 million and the deferred liability by $0.2 million. During the three months ended June 30, 2016, the Company recognized a $2.0 million milestone payment as deferred revenue under this license agreement and reduced the related note payable by $1.5 million and the deferred liability by $0.5 million. As of June 30, 2016, the amount of the note payable was $6.2 million, including $1.6 million accrued interest. As of June 30, 2016, the total deferred liability associated with the Medinet note was $5.3 million. The agreement will terminate upon expiration of the royalty term, upon which all licenses will become fully paid up, perpetual non-exclusive licenses. Either party may terminate the agreement for the other party’s uncured material breach or if specified conditions occur relating to the other party’s insolvency or bankruptcy, and the Company may terminate the agreement if Medinet challenges or assists a third party in challenging specified patent rights of the Company. If Medinet terminates the agreement upon the Company’s material breach or bankruptcy, Medinet is entitled to terminate the Company’s licenses to improvements and retain its royalty-bearing licenses from the Company. Lummy License Agreement On April 7, 2015, the Company and Lummy (Hong Kong) Co. Ltd. (“Lummy HK”), a wholly owned subsidiary of Chongqing Lummy Pharmaceutical Co. Ltd., entered into a license agreement (the “License Agreement”) whereby the Company granted to Lummy HK an exclusive license under the Arcelis technology, including patents, know-how and improvements to manufacture, develop and commercialize products for the treatment of cancer (“Licensed Product”) in China, Hong Kong, Taiwan and Macau (the “Territory”). Lummy HK also has a right of first negotiation with respect to a license under the Arcelis technology for the treatment of infectious diseases in the Territory. Under the terms of the License Agreement, the parties will share relevant data, and the Company will have a right to reference Lummy HK data for purposes of its development programs under the Arcelis technology. In addition, Lummy HK has granted to the Company an exclusive, royalty-free license under and to any and all Lummy HK improvements to the Arcelis technology conceived or reduced to practice by Lummy HK (“Lummy HK Improvements”) and Lummy HK data to develop and/or commercialize products (“Arcelis-Based Products”) outside the Territory, an exclusive, royalty-free license under and to any and all investigational new drug applications ("INDs") and other regulatory approvals and Lummy HK trademarks used for an Arcelis-Based Product to develop and/or commercialize an Arcelis-Based Product outside the Territory and a non-exclusive, worldwide, royalty-free license under any Lummy HK Improvements and Lummy HK data to manufacture Arcelis-Based Products anywhere in the world. Lummy HK has the right to reference Company’s data, INDs and other regulatory filings and submissions for the purpose of developing and obtaining regulatory approval of Licensed Products in the Territory. Pursuant to the License Agreement, Lummy HK will pay the Company royalties on net sales and up to an aggregate of $20.0 million upon the achievement of manufacturing, regulatory and commercial milestones. The License Agreement will terminate upon expiration of the last to expire royalty term for all Arcelis-Based Products, with each royalty term being the longer of the expiration of the last valid patent claim covering the applicable Arcelis-Based Product and 10 years from the first commercial sale of such Arcelis-Based Product. Either party may terminate the License Agreement for the other party’s uncured material breach or if specified conditions occur relating to the other party’s insolvency or bankruptcy. The Company may terminate the License Agreement if Lummy HK challenges or assists a third party in challenging specified patent rights of the Company. If Lummy HK terminates the License Agreement upon the Company’s material breach or bankruptcy, Lummy HK is entitled to terminate the licenses it granted to the Company and retain its licenses from the Company with respect to Arcelis-Based Products then in development or being commercialized, subject to Lummy HK’s continued obligation to pay royalties and milestones with respect to such Arcelis-Based Products.

Note 12 - Net Loss Per Share

Note 12 - Net Loss Per Share	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Earnings Per Share [Text Block]	12. Net Loss Per Share Basic and diluted net loss per share of common stock was determined by dividing net loss by the weighted average of shares of common stock outstanding during the period. The Company’s potentially dilutive shares, which include options to purchase common stock and warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be antidilutive. The following table presents the computation of basic and diluted net loss per share of common stock: Three Months Ended June 30, Six Months Ended June 30, 2015 2016 2015 2016 Net loss $ (19,604,818 ) $ (12,606,245 ) $ (37,151,033 ) $ (25,426,433 ) Weighted average common shares outstanding, basic and diluted 20,622,326 26,066,160 20,145,747 24,336,393 Net loss per share, basic and diluted $ (0.95 ) $ (0.48 ) $ (1.84 ) $ (1.04 ) The following potentially dilutive securities have been excluded from the computation of diluted weighted average shares outstanding, as they would be antidilutive: Three Months Ended June 30, Six Months Ended June 30, 2015 2016 2015 2016 Stock options outstanding 3,003,899 3,716,923 2,944,576 3,635,868 Warrants outstanding 82,781 2,854,320 82,781 1,724,422

Note 13 - Subsequent Event

Note 13 - Subsequent Event	6 Months Ended
	Jun. 30, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	13. Subsequent Event On August 2, 2016, the Company issued and sold 9,090,909 shares of common stock and warrants to purchase an aggregate of 6,818,181 shares of common stock in an underwritten public offering at a price to the public of $5.50 per share and accompanying warrant. The shares of common stock and warrants were sold in combination, with one warrant to purchase up to 0.75 of a share of common stock accompanying each share of common stock sold. The warrants have an exercise price of $5.50 per share, became immediately exercisable upon issuance and will expire on August 2, 2021. The aggregate net proceeds to the Company of the offering were approximately $48.2 million after deducting underwriting discounts and commissions and estimated offering expenses.

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Accordingly, the statements do not include all information and footnotes required by U.S. GAAP for annual consolidated financial statements. In the opinion of management, such interim financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of financial position, results of operations and cash flows for such periods. The results for the three and six months ended June 30, 2016 are not necessarily indicative of the results that may be expected for the year ended December 31, 2016 or future operating periods. The information included in these interim financial statements should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this Quarterly Report on Form 10-Q and the consolidated financial statements and footnotes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015. The Company’s consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Company has incurred losses in each year since inception and as of June 30, 2016, had an accumulated deficit of $304.4 million. Also, as of June 30, 2016, the Company’s current assets totaled $37.3 million compared with current liabilities of $17.9 million, and the Company had cash, cash equivalents and short-term investments of $34.8 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements for the three and six months ended June 30, 2016 do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to continue as a going concern. Until such time, if ever, as the Company can generate substantial product revenues, it expects to seek to raise additional funds through a combination of equity offerings, debt financings, government contracts, government and other third party grants or other third party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. There can be no assurance that the Company will be able to generate funds in these manners, on terms acceptable to the Company, on a timely basis or at all. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition and the Company could be forced to delay, reduce, terminate or eliminate its product development programs. The condensed consolidated financial statements include the accounts of the Company and DC Bio Corp., the Company’s Canadian wholly-owned subsidiary, an unlimited liability corporation incorporated in the Province of Nova Scotia. Significant intercompany transactions and accounts have been eliminated.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less as of the date of purchase to be cash equivalents. Cash deposits are all in financial institutions in the United States, Canada and the European Union. The Company maintains cash in accounts which are in excess of federally insured limits. As of December 31, 2015 and June 30, 2016, $5,913,144 and $34,580,164, respectively, in cash and cash equivalents were uninsured.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash The Company had restricted cash of $740,000 as of each of December 31, 2015 and June 30, 2016, which consists of funds maintained in a separate deposit account to secure a letter of credit issued by a bank to the landlord under a lease agreement for the Company’s new corporate headquarters and primary manufacturing facility (see Note 7).
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases (Topic 842) Leases In May 2015, the FASB issued a new standard which removes the requirement to categorize the investments for which fair value is measured using net asset value per share as a practical expedient for fair value within the fair value hierarchy. This standard is effective for the Company for reporting periods beginning after December 15, 2015 and is to be applied retrospectively; early adoption is permitted. The Company adopted this standard during the three months ended March 31, 2016. There was no impact on the Company’s consolidated financial statements. In April 2015, the FASB issued a new standard update which requires debt issuance costs to be presented in the consolidated balance sheet as a direct deduction from the associated debt liability. This standard became effective for the Company beginning on January 1, 2016 and isapplied on a retrospective basis. As a result, deferred financing costs of $93,503 and $85,002 were reclassified to long-term debt as of December 31, 2015 and March 31, 2016, respectively. In August 2014, the FASB issued a new standard update that specifies the responsibility that an entity’s management has to evaluate whether there is substantial doubt about the entity’s ability to continue as a going concern. The standard is effective for interim and annual periods beginning after December 15, 2016, and is not expected to have an effect on the Company’s consolidated financial statements. In May 2014, the FASB issued a new accounting standard update pertaining to accounting for revenue from contracts with customers. The new guidance clarifies the principles for recognizing revenue and develops a common revenue standard for U.S. GAAP. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes the most current revenue recognition guidance. In July 2015, the FASB finalized a one-year delay in the effective date of this standard, which will now be effective for the Company beginning January 1, 2018, however early adoption is permitted any time after the original effective date, which for the Company is January 1, 2017. The Company is currently evaluating the impact that the implementation of this standard will have on the Company’s consolidated financial statements.

Note 2 - Fair Value of Financ21

Note 2 - Fair Value of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Quoted Prices Significant Significant Balance as of Assets Money-market funds $ 5,589,684 $ — $ — $ 5,589,684 Corporate debt securities – short-term — 1,003,160 — 1,003,160 Restricted cash 740,000 740,000 Total assets at fair value $ 6,329,684 $ 1,003,160 $ — $ 7,332,844 Quoted Prices Significant Significant Balance as of Assets Money-market funds $ 343,841 $ — $ — $ 343,841 Restricted cash 740,000 740,000 Total assets at fair value $ 1,083,841 $ — $ — $ 1,083,841
Financial Instruments [Table Text Block]	As of December 31, 2015 Amortized Cost Gross Gross Aggregate Money-market funds $ 5,589,684 $ — $ — $ 5,589,684 Corporate debt securities – short term 1,003,431 — (271 ) 1,003,160 Restricted cash 740,000 — — 740,000 $ 7,333,115 $ — $ (271 ) $ 7,332,844 As of June 30, 2016 Amortized Cost Gross Gross Aggregate Money-market funds $ 343,841 $ — $ — $ 343,841 Restricted cash 740,000 — — 740,000 $ 1,083,841 $ — $ — $ 1,083,841

Note 3 - Property and Equipme22

Note 3 - Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2016
Depreciation and Amortization Expense [Member]
Notes Tables
Property, Plant and Equipment [Table Text Block]	Three months ended June 30, 2015 $ 181,530 Three months ended June 30, 2016 $ 237,996 Six months ended June 30, 2015 $ 347,962 Six months ended June 30, 2016 $ 439,738
Property, Plant and Equipment [Table Text Block]	December 31, 2015 June 30, 2016 Office furniture and equipment $ 681,954 $ 681,954 Computer equipment 970,689 1,099,033 Computer software 629,948 3,143,722 Laboratory equipment 5,916,539 5,908,068 Leasehold improvements 2,664,669 2,664,669 Asset related to facility lease obligation 7,630,660 7,640,660 Construction-in-progress 12,656,260 17,274,267 31,150,719 38,412,373 Less: Accumulated depreciation and amortization (8,844,335 ) (9,267,285 ) Property and equipment, net $ 22,306,384 $ 29,145,088

Note 5 - Notes Payable (Tables)

Note 5 - Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Debt [Table Text Block]	December 31, June 30, Notes payable under the venture loan and security agreement, including accrued interest $ 25,265,451 $ 25,431,010 Less debt discount and debt issuance costs (495,229 ) (407,819 ) Notes payable under the venture loan and security agreement, net 24,770,222 25,023,191 Promissory note payable to Medinet, including accrued interest 7,489,565 6,228,635 Other notes payable 46,755 39,026 Total notes payable 32,306,542 31,290,852 Less current portion (1,578,284 ) (6,787,283 ) Long-term portion of notes payable $ 30,728,258 $ 24,503,569

Note 9 - Stock Options and Wa24

Note 9 - Stock Options and Warrants (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2015 2016 2015 2016 Research and development $ 401,826 $ 997,090 $ 808,017 $ 1,434,285 General and administrative 496,249 637,083 1,004,573 1,073,111 Total stock-based compensation expense $ 898,075 $ 1,634,173 $ 1,812,590 $ 2,507,396
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Weighted Weighted Outstanding as of December 31, 2015 3,318,541 $ 6.24 Granted 1,210,106 $ 5.72 Exercised (20,995 ) $ 6.32 Cancelled (85,566 ) $ 7.01 Outstanding as of June 30, 2016 4,422,086 $ 6.08 8.15 Exercisable as of June 30, 2016 1,943,789 $ 5.93 7.08 Vested and expected to vest as of June 30, 2016 4,231,093 $ 6.08 8.11
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Stock Option Plan Employee Stock Purchase Plan Six Months Ended June 30, Six Months Ended June 30, 2015 2016 2015 2016 Risk-free interest rate 2.07 % 1.53 % 0.07 % 0.5 % Dividend yield 0 % 0 % 0 % 0 % Expected option term (in years) 7 7 0.5 0.5 Volatility 86 % 82 % 45 % 141 %
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Type of Warrant Number of Shares Exercise Price Expiration Common stock 1 $ 23,894.34 7/13/16 Common stock 82,780 $ 9.06 9/29/21 Common stock 2,683,261 $ 5.35 3/14/21 Common stock 4,109,005 $ 5.35 6/29/21

Note 12 - Net Loss Per Share (T

Note 12 - Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2016
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2015 2016 2015 2016 Net loss $ (19,604,818 ) $ (12,606,245 ) $ (37,151,033 ) $ (25,426,433 ) Weighted average common shares outstanding, basic and diluted 20,622,326 26,066,160 20,145,747 24,336,393 Net loss per share, basic and diluted $ (0.95 ) $ (0.48 ) $ (1.84 ) $ (1.04 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended June 30, Six Months Ended June 30, 2015 2016 2015 2016 Stock options outstanding 3,003,899 3,716,923 2,944,576 3,635,868 Warrants outstanding 82,781 2,854,320 82,781 1,724,422

Note 1 - Organization and Bas26

Note 1 - Organization and Basis of Presentation (Details Textual) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Jun. 30, 2016
Reclassification from Deferring Financing Costs to Long-term Debt [Member] | December 31, 2015 [Member]
Prior Period Reclassification Adjustment		$ 93,503
Reclassification from Deferring Financing Costs to Long-term Debt [Member]
Current Period Reclassification Adjustment	$ 85,002
Retained Earnings (Accumulated Deficit)		(278,958,707)	$ (304,385,140)
Assets, Current		8,720,295	37,279,003
Liabilities, Current		8,162,813	17,876,918
Cash, Cash Equivalents, and Short-term Investments			34,800,000
Cash, Uninsured Amount		5,913,144	34,580,164
Restricted Cash and Cash Equivalents, Current		$ 740,000	$ 740,000

Note 2 - Fair Value of Financ27

Note 2 - Fair Value of Financial Instruments (Details Textual) - USD ($) $ in Millions	Jun. 30, 2016	Dec. 31, 2015
Long-term Debt, Fair Value	$ 30.9	$ 32
Long-term Debt	$ 31.3	$ 32.4

Note 2 - Fair Value of Financ28

Note 2 - Fair Value of Financial Instruments (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]
Assets at fair value	$ 343,841	$ 5,589,684
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]
Assets at fair value
Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]
Assets at fair value
Money Market Funds [Member]
Assets at fair value	343,841	5,589,684
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Assets at fair value
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Assets at fair value		1,003,160
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Assets at fair value
Corporate Debt Securities [Member]
Assets at fair value		1,003,160
Restricted Cash [Member] | Fair Value, Inputs, Level 1 [Member]
Assets at fair value	740,000	740,000
Restricted Cash [Member] | Fair Value, Inputs, Level 2 [Member]
Assets at fair value
Restricted Cash [Member] | Fair Value, Inputs, Level 3 [Member]
Assets at fair value
Restricted Cash [Member]
Assets at fair value	740,000	740,000
Fair Value, Inputs, Level 1 [Member]
Assets at fair value	1,083,841	6,329,684
Fair Value, Inputs, Level 2 [Member]
Assets at fair value		1,003,160
Fair Value, Inputs, Level 3 [Member]
Assets at fair value
Assets at fair value	$ 1,083,841	$ 7,332,844

Note 2 - Financial Instruments

Note 2 - Financial Instruments (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Money Market Funds [Member]
Amortized Cost Basis	$ 343,841	$ 5,589,684
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Aggregate Fair Value	343,841	5,589,684
Short-term Investments [Member] | Corporate Debt Securities [Member]
Amortized Cost Basis		1,003,431
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses		(271)
Aggregate Fair Value		1,003,160
Restricted Cash [Member]
Amortized Cost Basis	740,000	740,000
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Aggregate Fair Value	740,000	740,000
Amortized Cost Basis	1,083,841	7,333,115
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses		(271)
Aggregate Fair Value	$ 1,083,841	$ 7,332,844

Note 3 - Property and Equipme30

Note 3 - Property and Equipment (Details Textual) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Construction in Progress [Member]
Accumulated Capitalized Interest Costs	$ 1,730,885	$ 880,334

Note 3 - Property and Equipme31

Note 3 - Property and Equipment (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Office Furniture and Equipment [Member]
Property and equipment	$ 681,954	$ 681,954
Computer Equipment [Member]
Property and equipment	1,099,033	970,689
Computer Software [Member]
Property and equipment	3,143,722	629,948
Laboratory Equipment [Member]
Property and equipment	5,908,068	5,916,539
Leasehold Improvements [Member]
Property and equipment	2,664,669	2,664,669
Assets Held under Capital Leases [Member]
Property and equipment	7,640,660	7,630,660
Property and equipment	38,412,373	31,150,719
Construction-in-progress	17,274,267	12,656,260
Less: Accumulated depreciation and amortization	(9,267,285)	(8,844,335)
Property and equipment, net	$ 29,145,088	$ 22,306,384

Note 3 - Depreciation and Amort

Note 3 - Depreciation and Amortization Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Three months ended June 30, 2015	$ 237,996	$ 181,530	$ 439,738	$ 347,962

Note 4 - Income Taxes (Details

Note 4 - Income Taxes (Details Textual)	6 Months Ended
	Jun. 30, 2016USD ($)
Income Tax Expense (Benefit)	$ 0

Note 5 - Notes Payable (Details

Note 5 - Notes Payable (Details Textual) - USD ($)	Sep. 29, 2014	Dec. 31, 2013	Nov. 30, 2013	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2015	Dec. 31, 2013	Feb. 07, 2019	Sep. 30, 2018	Aug. 02, 2016
Venture Loan and Security Agreement [Member] | Primary Tranche [Member] | Scenario, Forecast [Member]
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid									$ 625,000
Venture Loan and Security Agreement [Member] | Primary Tranche [Member] | Primary Payment Period [Member]
Debt Instrument, Term					1 year 180 days
Venture Loan and Security Agreement [Member] | Primary Tranche [Member] | Secondary Payment Period [Member]
Debt Instrument, Term					2 years
Venture Loan and Security Agreement [Member] | Primary Tranche [Member]
Debt Instrument Tranche Amount	$ 12,500,000
Proceeds from Loans	$ 12,500,000
Venture Loan and Security Agreement [Member] | Secondary Tranche [Member] | Subsequent Event [Member]
Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid								$ 625,000
Venture Loan and Security Agreement [Member] | LIBOR Rate In Excess of a Half a Percent [Member]
Debt Instrument, Basis Spread on Variable Rate	9.25%
Venture Loan and Security Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	8.75%
Venture Loan and Security Agreement [Member] | Maximum [Member]
Debt Instrument, Interest Rate, Stated Percentage	10.75%
Venture Loan and Security Agreement [Member] | Prepayment on or Before Twenty Four Months of Funding Date [Member]
Debt Instrument, Prepayment Penalty, Percentage of Balance				3.00%	3.00%
Venture Loan and Security Agreement [Member] | Prepayment After Twenty Four Months But on or Before Thirty Six Months [Member]
Debt Instrument, Prepayment Penalty, Percentage of Balance				2.00%	2.00%
Venture Loan and Security Agreement [Member] | Prepayment After Thirty Six Months of Funding Date [Member]
Debt Instrument, Prepayment Penalty, Percentage of Balance				1.00%	1.00%
Venture Loan and Security Agreement [Member]
Debt Instrument, Face Amount	$ 25,000,000
Loan Facility, Number of Tranches	2
Debt Instrument, One-Month LIBOR Basis Rate	0.50%
Debt Related Commitment Fees and Debt Issuance Costs	$ 449,796
Debt Instrument, Interest Rate Increase on Default				5.00%	5.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	82,780
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 9.06
Debt Instrument, Unamortized Discount	$ 338,673
December 2013 Note [Member] | Manufacturing License [Member]
Deferred Credits and Other Liabilities, Noncurrent				$ 2,000,000	$ 2,000,000	$ 1,000,000
December 2013 Note [Member]
Debt Instrument, Face Amount		$ 9,000,000					$ 9,000,000
Debt Instrument, Interest Rate, Stated Percentage		3.00%					3.00%
Proceeds from Notes Payable							$ 9,000,000
Notes Payable		$ 6,900,000		6,228,635	6,228,635	7,489,565	$ 6,900,000
Debt Instrument, Interest Rate, Effective Percentage		8.00%					8.00%
Deferred Credits and Other Liabilities, Noncurrent		$ 2,100,000		$ 5,300,000	5,300,000	3,800,000	$ 2,100,000
Debt Instrument, Increase, Accrued Interest					$ 1,600,000	1,300,000
November 2013 Note [Member]
Debt Instrument, Interest Rate, Stated Percentage				8.31%	8.31%
Proceeds from Notes Payable			$ 77,832
Notes Payable				$ 39,026	$ 39,026	46,754
Debt Instrument, Number of Payments				60	60
Subsequent Event [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										6,818,181
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 5.50
Medinet [Member]
Debt Instrument, Interest Rate, Stated Percentage		3.00%					3.00%
Proceeds from Notes Payable		$ 9,000,000
Notes Payable		$ 6,900,000		$ 6,200,000	$ 6,200,000		$ 6,900,000
Debt Instrument, Interest Rate, Effective Percentage		8.00%					8.00%
Reduction in Notes Payable				1,500,000	1,500,000	800,000
Reduction in Deferred Liability				500,000	500,000	200,000
Debt Instrument, Increase, Accrued Interest					1,600,000
Debt Instrument Tranche Amount				25,431,010	25,431,010	25,265,451
Notes Payable				31,290,852	31,290,852	32,306,542
Deferred Credits and Other Liabilities, Noncurrent				$ 6,778,500	$ 6,778,500	$ 5,321,000

Note 5 - Notes Payable (Detai35

Note 5 - Notes Payable (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015	Dec. 31, 2013
Horizon And Fortress Lenders [Member]
Less debt discount and debt issuance costs	$ (407,819)	$ (495,229)
Notes Payable	25,023,191	24,770,222
December 2013 Note [Member]
Notes Payable	6,228,635	7,489,565	$ 6,900,000
July 2012 Note [Member]
Other notes payable	39,026	46,755
Debt Instrument Tranche Amount	25,431,010	25,265,451
Notes Payable	31,290,852	32,306,542
Less current portion	(6,787,283)	(1,578,284)
Long-term portion of notes payable	$ 24,503,569	$ 30,728,258

Note 6 - Manufacturing Resear36

Note 6 - Manufacturing Research and Development Obligation (Details Textual) - USD ($)	Oct. 29, 2014	Jun. 30, 2016	Dec. 31, 2015
Invetech Pty Ltd [Member]
Deferred Research and Development Manufacturing Service Costs Percentage	30.00%
Maximum Deferred Research and Development Manufacturing Service Costs	$ 5,000,000
Interest Rate on Deferred Research and Development Manufacturing Costs	7.00%
Period from Trigger Event for Repayment of Deferred Costs	90 days
Invetech Pty Ltd [Member]
Number of Installments for Repayment in One Year	4
Number of Installments for Repayment in Two Years	8
Bonus Payment Upon Successful Completion of Clinical Trials Percentage of Payment	10.00%
Research and Development Obligation, Noncurrent		$ 8,000,000	$ 7,800,000
Research and Development Obligation Deferred Fees		5,200,000	5,200,000
Research and Development Obligation Estimated Bonus Payment		2,300,000	2,300,000
Research and Development Obligation Accrued Interest		500,000	300,000
Research and Development Obligation, Current		2,100,000
Contractual Obligation		25,000,000
Research and Development Obligation, Noncurrent		5,854,880	7,777,436
Research and Development Obligation, Current		$ 2,122,661

Note 7 - Facility Lease Oblig37

Note 7 - Facility Lease Obligation (Details Textual)	Aug. 18, 2014ft²	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)
Lease Agreement [Member] | Restricted Cash [Member]
Lessee Leasing Arrangements, Operating Leases, Letter of Credit				$ 740,000
Lease Agreement [Member]
Capital Leases, Balance Sheet, Assets by Major Class, Net		$ 7,200,000		7,200,000
Facility Lease Obligation Building Area | ft²	125,000
Payments to Acquire Property, Plant, and Equipment		1,700,000
Lessee Leasing Arrangements, Operating Leases, Number of Renewal Terms	6
Lessee Leasing Arrangements, Operating Leases, Term of Contract	10 years
Lessee Leasing Arrangements, Operating Leases, Renewal Term	5 years
Capital Lease, Future Monthly Payments		47,972
Security Deposit				1,325,000
Capital Lease Obligations, Noncurrent		7,600,000		7,600,000
Lease Agreement, Purchase Option		7,400,000
Payments to Acquire Property, Plant, and Equipment		5,635,239	$ 5,010,684
Capital Lease Obligations, Noncurrent		$ 7,159,627		$ 7,249,627

Note 8 - Stockholders' (Defic38

Note 8 - Stockholders' (Deficit) Equity (Details Textual)	Feb. 28, 2017USD ($)	Sep. 30, 2016USD ($)$ / sharesshares	Aug. 02, 2016USD ($)$ / sharesshares	Jun. 29, 2016USD ($)$ / sharesshares	Mar. 14, 2016USD ($)$ / sharesshares	Jan. 08, 2016USD ($)$ / sharesshares	May 08, 2015USD ($)	Aug. 08, 2016USD ($)shares	Jun. 30, 2016USD ($)shares	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)shares	Jun. 30, 2015USD ($)	Nov. 20, 2016	Mar. 04, 2016	Nov. 30, 2013$ / sharesshares
Private Placement [Member] | Investors [Member] | Scenario, Forecast [Member] | Maximum [Member]
Payments of Stock Issuance Costs	$ 140,000
Private Placement [Member] | Investors [Member] | Scenario, Forecast [Member]
Proceeds from Issuance or Sale of Equity	$ 60,000,000
Stock Issued During Period, Value, New Issues		$ 29,824,520
Stock Issued During Period, Shares, New Issues | shares		5,478,672
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		4,109,005
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares		0.75
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 5.35
Class of Warrant or Right, Term		5 years
Registration Rights Agreement, Registration Statement Not Filed, Liquidated Damages Pro Rata Payments, Investment Percentage	1.00%
Registration Rights Agreement, Registration Not Available to Cover Sales of Registrable Securities, Liquidated Damages Pro Rata Payments, Investment Percentage	1.00%
Private Placement [Member] | Investors [Member]
Stock Issued During Period, Value, New Issues				$ 29,824,520	$ 19,882,915
Stock Issued During Period, Shares, New Issues | shares				5,478,672	3,652,430
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				4,109,005	2,739,323
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares					0.75
Sale of Stock, Price Per Share | $ / shares					$ 5.44375
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 5.35	$ 5.35
Private Placement [Member] | Pharmstandard [Member] | Scenario, Forecast [Member]
Stock Issued During Period, Value, New Issues	$ 10,292,563
Private Placement [Member] | Pharmstandard [Member]
Securities Purchase Agreement, Beneficial Ownership Percentage, Voting Power Threshold														33.00%
Private Placement [Member]
Number of Tranches					3
Sales Agreement, At-the-market Offering [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues | shares								873,000
Proceeds from Issuance of Common Stock								$ 5,500,000
Sales Agreement, At-the-market Offering [Member]
Stock Issued During Period, Shares, New Issues | shares									800,392
Proceeds from Issuance of Common Stock									$ 5,100,000
Pharmstandard [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares															499,788
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares															$ 5.82
Cowen and Company LLC [Member] | Maximum [Member]
Common Stock Sales Agreement, Amount							$ 30,000,000
Common Stock Sales Agreement, Commission of Gross Proceeds							3.00%
Scenario, Forecast [Member]
Restricted Stock Awards, Lapsing Right of Repurchase, Percentage of Underlying Shares													100.00%
Common Stock [Member] | Nonemployee Directors [Member]
Stock Issued During Period, Shares, New Issues | shares									11,066		23,563
Stock Issued During Period, Value, Issued for Services									$ 67,835		$ 147,815
Common Stock [Member]
Share Price | $ / shares						$ 2.24
Employees [Member] | Restricted Stock [Member] | General and Administrative Expense [Member]
Allocated Share-based Compensation Expense									38,090		38,090
Employees [Member] | Restricted Stock [Member] | Research and Development Expense [Member]
Allocated Share-based Compensation Expense									5,139		5,139
Employees [Member] | Restricted Stock [Member]
Allocated Share-based Compensation Expense									43,229		43,229
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense									637,083	$ 496,249	1,073,111	$ 1,004,573
Research and Development Expense [Member]
Allocated Share-based Compensation Expense									997,090	401,826	1,434,285	808,017
Subsequent Event [Member]
Proceeds from Issuance or Sale of Equity			$ 48,200,000
Stock Issued During Period, Shares, New Issues | shares			9,090,909
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares			6,818,181
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares			0.75
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 5.50
Share Price | $ / shares			$ 5.50
Payments of Stock Issuance Costs											75,188
Allocated Share-based Compensation Expense									$ 1,634,173	$ 898,075	$ 2,507,396	$ 1,812,590
Stock Issued During Period, Shares, Restricted Stock Award, Gross | shares						296,936
Stock Issued During Period, Value, Restricted Stock Award, Gross						$ 665,137

Note 9 - Stock Options and Wa39

Note 9 - Stock Options and Warrants (Details Textual)	Jun. 29, 2016USD ($)$ / sharesshares	Mar. 14, 2016USD ($)$ / sharesshares	Feb. 29, 2016USD ($)$ / sharesshares	Aug. 31, 2015USD ($)$ / sharesshares	Nov. 30, 2013$ / sharesshares	Jun. 29, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2016USD ($)$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Feb. 27, 2015USD ($)$ / sharesshares	Mar. 01, 2016$ / shares	Sep. 01, 2015$ / shares	Mar. 02, 2015$ / shares	Sep. 29, 2014$ / sharesshares	Sep. 02, 2014$ / shares	Feb. 12, 2014shares	Jan. 31, 2014shares
The 2014 Plan [Member] | Initial Authorization [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																			1,951,182
The 2014 Plan [Member] | Additional Authorization [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																			357,841
The 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized							2,309,023		2,309,023	2,309,023
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percent of Shares Outstanding							4.00%		4.00%	4.00%
Common Stock, Capital Shares Reserved for Future Issuance							774,189		774,189	774,189
The 2008 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant																		381,250
The 2014 ESPP [Member] | Executive Committee Employees [Member]
Share Price | $ / shares							$ 5.95		$ 5.95	$ 5.95
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares							$ 7.41			$ 7.41
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							565,000			565,000
The 2014 ESPP [Member] | Employees and Non-employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											622,300
The 2014 ESPP [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate							10.00%		10.00%	10.00%
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent										85.00%
Employee Stock Purchase Plan (ESPP), Number of Shares Allocated			36,290	20,301								13,054
Share Price | $ / shares			$ 4.44	$ 6.21			$ 6.13		$ 6.13	$ 6.13		$ 9.02	$ 4.91	$ 6.24	$ 9.02		$ 9.83
Allocated Share-based Compensation Expense | $			$ 107,455	$ 72,800					$ 51,371			$ 54,508
Common Stock, Capital Shares Reserved for Future Issuance							276,708		276,708	276,708
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross							899,456	510,650		1,210,106
Employees and Non-employee Directors [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit | $ / shares											$ 7.05
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit | $ / shares											$ 9.01
Lenders and Affiliates [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																82,780
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares																$ 9.06
Private Placement [Member] | Investors [Member]
Stock Issued During Period, Value, New Issues | $	$ 29,824,520	$ 19,882,915
Stock Issued During Period, Shares, New Issues	5,478,672	3,652,430
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	4,109,005	2,739,323				4,109,005
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 5.35	$ 5.35				$ 5.35
Class of Warrant or Right, Exercised During Period						56,062
Proceeds from Warrant Exercises | $						$ 299,932
Pharmstandard [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					499,788
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares					$ 5.82
Conversion of Stock, Shares Issued					13,188,251
Allocated Share-based Compensation Expense | $							$ 1,634,173	$ 898,075		$ 2,507,396	$ 1,812,590
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares										$ 5.72
Number of Terminated Employees							18
Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost | $							$ 600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										1,210,106
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit | $ / shares							$ 5.71	$ 7.05		$ 2.16
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit | $ / shares							$ 10.97	$ 8.46		$ 10.97
Proceeds from Warrant Exercises | $										$ 299,932

Note 9 - Stock-based Compensati

Note 9 - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Research and Development Expense [Member]
Allocated Share-based Compensation Expense	$ 997,090	$ 401,826	$ 1,434,285	$ 808,017
General and Administrative Expense [Member]
Allocated Share-based Compensation Expense	637,083	496,249	1,073,111	1,004,573
Allocated Share-based Compensation Expense	$ 1,634,173	$ 898,075	$ 2,507,396	$ 1,812,590

Note 9 - Stock Option Activity

Note 9 - Stock Option Activity (Details) - $ / shares	6 Months Ended
	Jun. 30, 2016
Number of Shares Outstanding, Beginning Balance (in shares)	3,318,541
Weighted Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)	$ 6.24
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,210,106
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 5.72
Number of Shares Exercised (in shares)	(20,995)
Weighted Average Exercise Price, Exercised (in dollars per share)	$ 6.32
Number of Shares Cancelled (in shares)	(85,566)
Weighted Average Exercise Price, Cancelled (in dollars per share)	$ 7.01
Number of Shares Outstanding, Ending Balance (in shares)	4,422,086
Weighted Average Exercise Price, Outstanding, Ending Balance (in dollars per share)	$ 6.08
Weighted Average Contractual Term, Outstanding, Ending Balance	8 years 54 days
Number of Shares Exercisable (in shares)	1,943,789
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 5.93
Weighted Average Contractual Term, Exercisable	7 years 29 days
Number of Shares Vested and Expected to Vest (in shares)	4,231,093
Weighted Average Exercise Price, Vested and Expected to Vest (in dollars per share)	$ 6.08
Weighted Average Contractual Term, Vested and Expected to Vest	8 years 40 days

Note 9 - Stock Option Valuation

Note 9 - Stock Option Valuation Assumptions (Details)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Stock Option Plans [Member]
Risk-free interest rate	1.53%	2.07%
Dividend yield	0.00%	0.00%
Expected option term (in years)	7 years	7 years
Volatility	82.00%	86.00%
Employee Stock Purchase Plan [Member]
Risk-free interest rate	0.50%	0.07%
Dividend yield	0.00%	0.00%
Expected option term (in years)	182 days	182 days
Volatility	141.00%	45.00%

Note 9 - Outstanding Warrants (

Note 9 - Outstanding Warrants (Details)	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Warrant One [Member]
Common stock, Number of shares (in shares) | shares	1
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 23,894.34
Common stock, Expiration Date(s)	Jul. 13, 2016
Warrant Two [Member]
Common stock, Number of shares (in shares) | shares	82,780
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 9.06
Common stock, Expiration Date(s)	Sep. 29, 2021
Warrant Three [Member]
Common stock, Number of shares (in shares) | shares	2,683,261
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 5.35
Common stock, Expiration Date(s)	Mar. 14, 2021
Warrant Four [Member]
Common stock, Number of shares (in shares) | shares	4,109,005
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 5.35
Common stock, Expiration Date(s)	Jun. 29, 2021

Note 10 - Revenue and Concent44

Note 10 - Revenue and Concentration of Credit Risk (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		118 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Dec. 31, 2015	Sep. 18, 2014	Sep. 30, 2006
NIH & NIAID [Member] | Initial [Member] | Operating Expense [Member]
Unattained Funds, Contracted Commitment								$ 38,400,000
NIH & NIAID [Member] | Initial [Member] | Other Specified [Member]
Unattained Funds, Contracted Commitment								1,400,000
NIH & NIAID [Member] | Additional [Member]
Unattained Funds, Contracted Commitment	$ 5,400,000		$ 5,400,000		$ 5,400,000		$ 500,000
NIH & NIAID [Member]
Unattained Funds, Contracted Commitment								$ 39,800,000
Revenues	461,143	$ 79,891	552,572	$ 243,606	37,700,000
Remaining Unattained Funds Contracted Commitment	2,100,000		2,100,000		2,100,000
Accounts Receivable, Net, Current	461,143		461,143		$ 461,143	$ 73,818
Revenues	$ 488,643	$ 107,391	$ 635,072	$ 286,162

Note 11 - Collaboration Agree45

Note 11 - Collaboration Agreements (Details Textual) - USD ($)	1 Months Ended				3 Months Ended	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Jul. 31, 2015	Dec. 31, 2013	Jul. 31, 2013	Jun. 30, 2016	Jun. 30, 2016	Dec. 31, 2015	Nov. 30, 2013	Aug. 31, 2013
Maximum [Member] | Pharmstandard [Member]
Royalties Percent of Net Sales									20.00%
Maximum [Member] | Green Cross [Member]
Royalties Percent of Net Sales				20.00%
Maximum [Member] | Medinet [Member] | Developmental and Regulatory Milestones [Member]
Royalty Guarantees, Commitments, Amount			$ 9,000,000
Pharmstandard [Member] | Scenario, Plan [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								499,788
Pharmstandard [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights								499,788
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 5.82
Green Cross [Member] | Initial Submission of Application for Regulatory Approval [Member]
Royalty Guarantees, Commitments, Amount				$ 500,000
Green Cross [Member] | Initial Regulatory Approval [Member]
Royalty Guarantees, Commitments, Amount				$ 500,000
Green Cross [Member]
Royalty Contract Term				15 years
Medinet [Member] | Nonsoftware License Arrangement [Member]
Deferred Credits and Other Liabilities, Noncurrent			1,000,000
Medinet [Member] | Below Market Rate Adjustment [Member]
Deferred Credits and Other Liabilities, Noncurrent	$ 5,300,000		2,100,000		$ 5,300,000	$ 5,300,000
Medinet [Member]
Royalty Guarantees, Commitments, Amount			5,000,000
Proceeds from License Fees Received	2,000,000	$ 1,000,000	1,000,000
Proceeds from Notes Payable			9,000,000
Notes Payable	6,200,000		$ 6,900,000		6,200,000	6,200,000
Debt Instrument, Interest Rate, Stated Percentage			3.00%
Debt Instrument, Interest Rate, Effective Percentage			8.00%
Deferred Revenue							$ 1,000,000
Reduction in Notes Payable					1,500,000	1,500,000	800,000
Reduction in Deferred Liability					500,000	500,000	200,000
Deferred Revenue, Additions					2,000,000
Debt Instrument, Increase, Accrued Interest						1,600,000
Medinet [Member]
Debt Instrument, Face Amount			$ 9,000,000
Notes Payable	31,290,852				31,290,852	31,290,852	32,306,542
Deferred Credits and Other Liabilities, Noncurrent	$ 6,778,500				$ 6,778,500	6,778,500	$ 5,321,000
Revenue Recognition Milestone Method, Maximum Revenue						$ 20,000,000
License Agreement Royalty Term						10 years

Note 12 - Basic and Diluted Net

Note 12 - Basic and Diluted Net Loss Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Net loss	$ (12,606,245)	$ (19,604,818)	$ (25,426,433)	$ (37,151,033)
Weighted average common shares outstanding, basic and diluted (in shares)	26,066,160	20,622,326	24,336,393	20,145,747
Net loss per share, basic and diluted (in dollars per share)	$ (0.48)	$ (0.95)	$ (1.04)	$ (1.84)

Note 12 - Antidilutive Securiti

Note 12 - Antidilutive Securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Employee Stock Option [Member]
Antidilutive Securities (in shares)	3,716,923	3,003,899	3,635,868	2,944,576
Warrant [Member]
Antidilutive Securities (in shares)	2,854,320	82,781	1,724,422	82,781

Note 13 - Subsequent Event (Det

Note 13 - Subsequent Event (Details Textual) - Subsequent Event [Member] $ / shares in Units, $ in Millions	Aug. 02, 2016USD ($)$ / sharesshares
Stock Issued During Period, Shares, New Issues	9,090,909
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	6,818,181
Share Price | $ / shares	$ 5.50
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	0.75
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 5.50
Proceeds from Issuance or Sale of Equity | $	$ 48.2